The national audit further indicates that 12% of women use potentially harmful medications (ACE inhibitors, statins, and other adverse diabetes medications) before pregnancy, increasing the risk of adverse fetal exposure during organogenesis, a critical phase of pregnancy.7 8 Delayed referrals to specialist diabetes maternity clinics among women with type 2 diabetes as compared with women with type 1 diabetes further contributes to the risk of congenital malformations caused by deleterious medication exposure.7 This evidence concerns the gene ACE and type 2 diabetes mellitus.